secwatch.observer — SEC 8-K summary
======================================

Issuer:     Incannex Healthcare Inc. (IXHL)
CIK:        0001873875
Form:       8-K
Filed at:   2026-08-11T11:30:34+00:00
Accession:  0001213900-26-087493
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incannex receives final A$5.1M R&D tax refund; 2026 non-dilutive capital tops A$11.2M
--------------------------------------------------------------------------------

- Received final A$5,102,788.30 refund under Australian R&D Tax Incentive Program on Aug 11, 2026.
- Combined with prior A$6,039,162.43, total 2026 non-dilutive proceeds exceed A$11.2 million.
- Refund follows approval of overseas findings and amendment of FY25 income tax return.
- Funds strengthen debt-free balance sheet; support clinical assets IHL-42X and PSX-001.
- Company expects additional R&D tax incentive funding in 2027 for eligible activities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1873875/000121390026087493/0001213900-26-087493-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1873875/000121390026087493/ea0301333-8k_incannex.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-087493

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer